Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Vedolizumab Q4W in Japanese UC/CD Patients With Secondary Loss of Response on Q8W
jRCT2031200371Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (2 cohorts), sponsored by Takeda. Primary endpoints: Clinical response at Week 12 based on modified Mayo score in UC cohort and Clinical response at Week 12 in CD cohort. Started Jun 2021; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on jRCT2031200371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200371.